ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA
TOULOUSE, France--(BUSINESS WIRE)--Regulatory News:
Under the liquidity agreement covering the shares of ABIONYX Pharma (FR0012616852 – ABNX FP) entrusted to TP ICAP (Europe), the following assets were held in the liquidity account as of June 30, 2026:
- Number of shares: 118,866 shares
- Cash balance: €96,894.38
During the first half of 2026, a total of:
PURCHASES | 282,460 shares | €933,897.51 | 361 transactions |
SALE | 226,618 securities | €782,823.64 | 283 transactions |
It should be noted that as of the half-yearly balance sheet dated December 31, 2025, the following assets were recorded in the cash account:
- Number of shares: 63,024 shares
- Cash balance: €257,777.69
It is noted that upon the establishment of the liquidity agreement, the following assets were made available:
- Number of shares: 131,000 shares
- Cash balance: €40,801.20
APPENDIX H1 2026
Purchases | Sales | |||||
ABNX FP | Number of Transactions | Number of Securities | Capital in EUR | Number of Transactions | Number of securities | Capital in EUR |
Total | 361 | 282,460 | 933,897.51 | 283 | 226,618 | 783,823.64 |
20260101 | 0 | 0 | 0.00 | 0 | 0 | 0.00 |
20260102 | 1 | 1 | 3.86 | 6 | 6,971 | 27,579.56 |
20260105 | 5 | 7,061 | 26,946.26 | 1 | 1 | 3.96 |
20260106 | 2 | 2,051 | 7,527.21 | 2 | 871 | 3,266.21 |
20260107 | 3 | 2,711 | 10,063.36 | 3 | 1,811 | 6,909.36 |
20260108 | 4 | 4,091 | 15,043.56 | 1 | 1 | 3.76 |
20260109 | 1 | 1 | 3.64 | 3 | 1,941 | 7,152.84 |
20260112 | 1 | 1 | 3.68 | 3 | 1,881 | 7,082.18 |
20260113 | 2 | 1,991 | 7,267.22 | 3 | 949 | 3,541.20 |
20260114 | 4 | 4,061 | 14,770.64 | 1 | 1 | 3.74 |
20260115 | 1 | 1 | 3.62 | 3 | 1,981 | 7,221.02 |
20260116 | 1 | 1 | 3.64 | 4 | 3,771 | 13,941.24 |
20260119 | 4 | 4,151 | 15,089.66 | 3 | 1,821 | 6,874.46 |
20260120 | 4 | 3,951 | 14,564.30 | 1 | 1 | 3.70 |
20260121 | 3 | 2,481 | 9,085.50 | 1 | 1 | 3.70 |
20260122 | 1 | 1 | 3.79 | 5 | 6,071 | 23,288.19 |
20260123 | 3 | 2,521 | 9,660.60 | 5 | 5,521 | 22,070.20 |
20260126 | 4 | 3,841 | 15,378.82 | 2 | 891 | 3,688.72 |
20260127 | 3 | 2,441 | 9,671.28 | 1 | 1 | 3.98 |
20260128 | 2 | 1,751 | 6,846.45 | 2 | 224 | 893.72 |
20260129 | 4 | 3,531 | 13,678.17 | 2 | 366 | 1,460.32 |
20260130 | 3 | 2,251 | 8,535.84 | 1 | 1 | 3.84 |
20260202 | 1 | 1,600 | 6,032.00 | 2 | 1,061 | 4,084.78 |
20260203 | 2 | 1,561 | 5,963.08 | 3 | 2,171 | 8,499.88 |
20260204 | 3 | 2,171 | 8,210.75 | 1 | 1 | 3.85 |
20260205 | 4 | 3,221 | 11,908.74 | 1 | 1 | 3.74 |
20260206 | 4 | 3,071 | 11,200.58 | 1 | 1 | 3.68 |
20260209 | 3 | 1,921 | 6,957.99 | 1 | 1 | 3.69 |
20260210 | 1 | 1 | 3.67 | 4 | 4,821 | 17,847.67 |
20260211 | 4 | 3,071 | 11,169.88 | 1 | 1 | 3.68 |
20260212 | 1 | 1 | 3.55 | 2 | 1,181 | 4,251.55 |
20260213 | 3 | 1,991 | 7,092.01 | 1 | 1 | 3.61 |
20260216 | 5 | 4,406 | 15,279.94 | 1 | 1 | 3.59 |
20260217 | 1 | 1 | 3.43 | 2 | 1,251 | 4,365.93 |
20260218 | 3 | 1,851 | 6,376.19 | 1 | 1 | 3.49 |
20260219 | 4 | 2,721 | 9,257.88 | 1 | 1 | 3.48 |
20260220 | 4 | 2,581 | 8,678.29 | 1 | 1 | 3.39 |
20260223 | 5 | 3,697 | 12,071.27 | 3 | 2,701 | 9,237.73 |
20260224 | 4 | 2,411 | 7,986.25 | 1 | 1 | 3.35 |
20260225 | 3 | 1,521 | 4,920.08 | 1 | 1 | 3.28 |
20260226 | 1 | 1 | 3.27 | 3 | 2,841 | 9,347.27 |
20260227 | 1 | 1 | 3.34 | 4 | 5,441 | 18,496.64 |
20260302 | 6 | 5,511 | 17,690.22 | 1 | 1 | 3.22 |
20260303 | 6 | 4,901 | 15,838.37 | 1 | 1 | 3.37 |
20260304 | 1 | 1 | 3.16 | 5 | 8,471 | 27,722.36 |
20260305 | 2 | 501 | 1,628.33 | 3 | 2,661 | 8,888.13 |
20260306 | 2 | 1,351 | 4,336.79 | 3 | 2,611 | 8,616.59 |
20260309 | 4 | 2,831 | 9,178.97 | 2 | 1,261 | 4,224.27 |
20260310 | 1 | 1 | 3.34 | 6 | 9,651 | 32,795.94 |
20260311 | 4 | 3,241 | 10,929.88 | 1 | 1 | 3.48 |
20260312 | 2 | 1,491 | 4,965.10 | 2 | 1,191 | 4,061.30 |
20260313 | 4 | 3,091 | 10,199.83 | 1 | 1 | 3.33 |
20260316 | 3 | 1,961 | 6,323.71 | 3 | 1,650 | 5,469.48 |
20260317 | 1 | 1 | 3.27 | 3 | 2,561 | 8,579.67 |
20260318 | 3 | 1,991 | 6,619.47 | 1 | 1 | 3.37 |
20260319 | 4 | 2,971 | 9,633.40 | 1 | 1 | 3.30 |
20260320 | 2 | 1,391 | 4,381.70 | 2 | 1,291 | 4,169.90 |
20260323 | 4 | 2,911 | 8,935.88 | 4 | 2,779 | 8,930.84 |
20260324 | 4 | 2,881 | 8,995.93 | 2 | 1,291 | 4,169.93 |
20260325 | 2 | 1,371 | 4,250.16 | 1 | 1 | 3.16 |
20260326 | 5 | 4,311 | 12,983.99 | 1 | 1 | 3.09 |
20260327 | 1 | 1 | 3.25 | 11 | 23,201 | 76,137.55 |
20260330 | 1 | 1 | 3.97 | 10 | 15,501 | 61,966.67 |
20260331 | 5 | 6,751 | 24,540.66 | 1 | 1 | 3.66 |
20260401 | 3 | 2,671 | 9,701.24 | 4 | 3,771 | 14,224.24 |
20260402 | 3 | 2,691 | 9,800.85 | 1 | 1 | 3.65 |
20260403 | 0 | 0 | 0.00 | 0 | 0 | 0.00 |
20260406 | 0 | 0 | 0.00 | 0 | 0 | 0.00 |
20260407 | 1 | 1 | 3.70 | 1 | 1 | 3.70 |
20260408 | 1 | 1 | 3.61 | 6 | 7,201 | 26,219.81 |
20260409 | 3 | 2,931 | 10,498.91 | 1 | 1 | 3.61 |
20260410 | 1 | 1 | 3.57 | 2 | 911 | 3,288.67 |
20260413 | 4 | 4,351 | 15,391.96 | 1 | 1 | 3.56 |
20260414 | 2 | 954 | 3,377.22 | 5 | 5,701 | 21,042.10 |
20260415 | 1 | 1 | 3.76 | 5 | 5,301 | 20,414.16 |
20260416 | 3 | 2,921 | 11,105.66 | 2 | 821 | 3,193.66 |
20260417 | 1 | 1 | 3.81 | 5 | 5,031 | 19,675.91 |
20260420 | 4 | 4,551 | 17,398.14 | 1 | 1 | 3.84 |
20260421 | 4 | 4,411 | 16,463.56 | 1 | 1 | 3.76 |
20260422 | 3 | 2,781 | 10,211.94 | 1 | 1 | 3.74 |
20260423 | 2 | 1,981 | 7,191.04 | 1 | 1 | 3.64 |
20260424 | 4 | 4,011 | 14,348.32 | 1 | 1 | 3.62 |
20260427 | 3 | 2,318 | 8,214.59 | 1 | 1 | 3.55 |
20260428 | 3 | 2,421 | 8,551.15 | 2 | 1,061 | 3,840.75 |
20260429 | 3 | 2,411 | 8,401.70 | 2 | 1,081 | 3,891.60 |
20260430 | 3 | 2,381 | 8,201.90 | 1 | 1 | 3.50 |
20260501 | 0 | 0 | 0.00 | 0 | 0 | 0.00 |
20260504 | 3 | 2,311 | 7,868.36 | 2 | 1,131 | 3,947.16 |
20260505 | 3 | 2,291 | 7,708.49 | 3 | 2,311 | 7,996.29 |
20260506 | 1 | 1 | 3.42 | 5 | 6,801 | 23,821.12 |
20260507 | 1 | 1 | 3.59 | 5 | 6,281 | 22,994.29 |
20260508 | 3 | 2,701 | 9,621.00 | 2 | 961 | 3,507.60 |
20260511 | 1 | 1 | 3.57 | 4 | 3,941 | 14,254.37 |
20260512 | 3 | 2,781 | 9,933.83 | 3 | 1,901 | 6,986.43 |
20260513 | 1 | 1 | 3.68 | 4 | 3,751 | 14,017.48 |
20260514 | 1 | 1 | 3.71 | 3 | 1,811 | 6,746.41 |
20260515 | 3 | 2,911 | 10,660.27 | 1 | 1 | 3.67 |
20260518 | 4 | 4,411 | 15,514.43 | 1 | 1 | 3.63 |
20260519 | 1 | 1 | 3.50 | 1 | 1 | 3.50 |
20260520 | 3 | 2,751 | 9,606.66 | 1 | 1 | 3.56 |
20260521 | 4 | 4,011 | 13,947.22 | 1 | 1 | 3.52 |
20260522 | 4 | 3,911 | 13,111.16 | 3 | 2,151 | 7,464.26 |
20260525 | 1 | 1 | 3.37 | 4 | 4,321 | 14,905.17 |
20260526 | 2 | 914 | 3,116.80 | 2 | 1,031 | 3,598.17 |
20260527 | 11 | 17,411 | 53,176.77 | 1 | 1 | 3.07 |
20260528 | 6 | 7,131 | 21,135.56 | 1 | 1 | 3.06 |
20260529 | 3 | 2,111 | 6,005.20 | 1 | 1 | 2.90 |
20260601 | 3 | 2,041 | 5,765.23 | 2 | 1,401 | 4,048.83 |
20260602 | 4 | 2,390 | 6,659.66 | 1 | 1 | 2.80 |
20260603 | 3 | 1,961 | 5,407.18 | 1 | 1 | 2.78 |
20260604 | 4 | 2,881 | 7,839.44 | 1 | 1 | 2.74 |
20260605 | 1 | 1 | 2.72 | 4 | 6,011 | 16,557.92 |
20260608 | 3 | 2,041 | 5,546.13 | 1 | 1 | 2.73 |
20260609 | 3 | 1,971 | 5,296.83 | 2 | 1,461 | 4,017.73 |
20260610 | 3 | 1,961 | 5,250.31 | 1 | 1 | 2.71 |
20260611 | 1 | 1 | 2.66 | 2 | 1,491 | 4,010.76 |
20260612 | 1 | 1 | 2.72 | 3 | 2,961 | 8,068.92 |
20260615 | 3 | 2,061 | 5,538.66 | 2 | 1,421 | 3,914.86 |
20260616 | 5 | 4,901 | 12,736.29 | 1 | 1 | 2.69 |
20260617 | 1 | 1 | 2.56 | 3 | 1,511 | 3,868.36 |
20260618 | 10 | 10,945 | 25,700.63 | 1 | 1 | 2.37 |
20260619 | 4 | 2,791 | 6,152.77 | 1 | 1 | 2.27 |
20260622 | 1 | 1 | 2.22 | 1 | 1 | 2.22 |
20260623 | 2 | 1,041 | 2,290.23 | 1 | 1 | 2.23 |
20260624 | 4 | 2,571 | 5,642.25 | 1 | 1 | 2.25 |
20260625 | 6 | 3,842 | 8,014.42 | 1 | 1 | 2.09 |
20260626 | 4 | 2,351 | 4,783.08 | 1 | 1 | 2.08 |
20260629 | 2 | 1,081 | 2,172.85 | 2 | 1,801 | 3,728.05 |
20260630 | 2 | 29 | 58.88 | 5 | 10,571 | 22,546.84 |
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biopharmaceutical company focused on sepsis and critical care, developing breakthrough biotherapies for serious diseases for which there are no effective treatments. Through its proprietary apoA-I-based technology platform, ABIONYX Pharma designs innovative biopharmaceuticals and next-generation HDL vectors that target the immune-inflammatory dysregulation at the heart of sepsis and other severe diseases. Driven by recognized scientific expertise, a differentiated pipeline, and an expanding global clinical network, ABIONYX Pharma aims to redefine therapeutic standards for sepsis and become a key player in intensive care.
Contacts
ABIONYX Pharma
infos@abionyx.com
